1
|
Lebon D, Collet L, Djordjevic S, Gomila C, Ouled‐Haddou H, Platon J, Demont Y, Marolleau J, Caulier A, Garçon L. PIEZO1 is essential for the survival and proliferation of acute myeloid leukemia cells. Cancer Med 2024; 13:e6984. [PMID: 38334477 PMCID: PMC10854442 DOI: 10.1002/cam4.6984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Revised: 01/06/2024] [Accepted: 01/19/2024] [Indexed: 02/10/2024] Open
Abstract
INTRODUCTION Leukemogenesis is a complex process that interconnects tumoral cells with their microenvironment, but the effect of mechanosensing in acute myeloid leukemia (AML) blasts is poorly known. PIEZO1 perceives and transmits the constraints of the environment to human cells by acting as a non-selective calcium channel, but very little is known about its role in leukemogenesis. RESULTS For the first time, we show that PIEZO1 is preferentially expressed in healthy hematopoietic stem and progenitor cells in human hematopoiesis, and globally overexpressed in AML cells. In AML subtypes, PIEZO1 expression associates with favorable outcomes as better overall (OS) and disease-free survival (DFS). If PIEZO1 is expressed and functional in THP1 leukemic myeloid cell line, its chemical activation doesn't impact the proliferation, differentiation, nor survival of cells. However, the downregulation of PIEZO1 expression dramatically reduces the proliferation and the survival of THP1 cells. We show that PIEZO1 knock-down blocks the cell cycle in G0/G1 phases of AML cells, impairs the DNA damage response pathways, and critically increases cell death by triggering extrinsic apoptosis pathways. CONCLUSIONS Altogether, our results reveal a new role for PIEZO1 mechanosensing in the survival and proliferation of leukemic blasts, which could pave the way for new therapeutic strategies to target AML cells.
Collapse
Affiliation(s)
- Delphine Lebon
- HEMATIM UR4666Université Picardie Jules VerneAmiensFrance
- Hématologie Clinique et Thérapie Cellulaire, CHU Amiens‐PicardieAmiensFrance
| | - Louison Collet
- HEMATIM UR4666Université Picardie Jules VerneAmiensFrance
- Hématologie Clinique et Thérapie Cellulaire, CHU Amiens‐PicardieAmiensFrance
| | | | - Cathy Gomila
- HEMATIM UR4666Université Picardie Jules VerneAmiensFrance
| | | | - Jessica Platon
- HEMATIM UR4666Université Picardie Jules VerneAmiensFrance
| | - Yohann Demont
- HEMATIM UR4666Université Picardie Jules VerneAmiensFrance
- Service d'Hématologie Biologie, CHU Amiens‐PicardieAmiensFrance
| | - Jean‐Pierre Marolleau
- HEMATIM UR4666Université Picardie Jules VerneAmiensFrance
- Hématologie Clinique et Thérapie Cellulaire, CHU Amiens‐PicardieAmiensFrance
| | - Alexis Caulier
- HEMATIM UR4666Université Picardie Jules VerneAmiensFrance
- Division of Hematology/Oncology Boston Children's HospitalBostonMassachusettsUSA
- Department of Medical and Population GeneticsThe Broad Institute of Harvard and MITCambridgeMassachusettsUSA
| | - Loïc Garçon
- HEMATIM UR4666Université Picardie Jules VerneAmiensFrance
- Service d'Hématologie Biologie, CHU Amiens‐PicardieAmiensFrance
| |
Collapse
|
2
|
Payrard-Starck C, Fourcade A, An Nguyen T, Tissot V, Doucet L, Marolleau J, Lucas C, Fournier G, Valeri A. Direct comparison between Grade Group assessed on systematic and MRI/ultrasound fusion targeted biopsies correlated to the radical prostatectomy specimens in patients with prostate cancer. Prog Urol 2023; 33:265-271. [PMID: 36740508 DOI: 10.1016/j.purol.2023.01.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2022] [Revised: 10/02/2022] [Accepted: 01/16/2023] [Indexed: 02/06/2023]
Abstract
OBJECTIVES To compare the correlation of Gleason score (GS) and ISUP grade determined by prostate biopsies (PBx) and radical prostatectomy (RP) specimens according to the biopsy technique: ultrasound randomised (RBx) vs. MRI/ultrasound fusion targeted (TBx). MATERIALS AND METHODS Between March 2013 and June 2018, we retrospectively included patients who underwent RP for prostate cancer (PCa) histopathologically proven by RBx and/or TBx. All patients had a prebiopsy MRI by a single radiologist (using PI-RADS score), then transrectal RBx (12cores, blinded to MRI lesions) and TBx (2-4 cores/target) with elastic MRI/ultrasound fusion (UroStation™, Koelis, Grenoble, France). Histological findings were compared: PBx vs. RP. RESULTS One hundred and four patients underwent RP after RBx and/or TBx. ISUP concordance rate was better with the association RBx+TBx 49% (51/104) vs. 43.3% with TBx (P=0.07) and 43.3% with RBx (P=0.13). With RBx, 50% of the patients were downgraded (52/104) against 42.3% (44/104) with TBx (P=0.088). The association RBx+TBx significantly decreased the rate of downgrading of the ISUP score compared to the ISUP score of RP 35.6% (37/104) vs. RBx (50%, P=0.0001) and vs. TBx (42.3%, P=0.016). CONCLUSION In half of cases, the ISUP score was underestimated in RBx compared to RP specimens. Adding TBx to RBx significantly reduced downgrading. The combination of both biopsy techniques appeared to be the best protocol to get closer to ISUP score and GS of the RP specimens. LEVEL OF EVIDENCE C.
Collapse
Affiliation(s)
- C Payrard-Starck
- Urology Department, CHU Brest, Brest, France; Faculté de Médecine et des Sciences de la Santé, Université de Brest, Brest, France.
| | - A Fourcade
- Urology Department, CHU Brest, Brest, France
| | - T An Nguyen
- Urology Department, CHU Brest, Brest, France; Faculté de Médecine et des Sciences de la Santé, Université de Brest, Brest, France; LaTIM, Inserm, UMR 1101, CHU Brest, Brest, France
| | - V Tissot
- Radiology Department, CHU Brest, Brest, France
| | - L Doucet
- Pathology Department, CHU Brest, Brest, France
| | - J Marolleau
- Urology Department, CHU Brest, Brest, France
| | - C Lucas
- Urology Department, CHU Brest, Brest, France; Faculté de Médecine et des Sciences de la Santé, Université de Brest, Brest, France
| | - G Fournier
- Urology Department, CHU Brest, Brest, France; Faculté de Médecine et des Sciences de la Santé, Université de Brest, Brest, France; LaTIM, Inserm, UMR 1101, CHU Brest, Brest, France
| | - A Valeri
- Urology Department, CHU Brest, Brest, France; Faculté de Médecine et des Sciences de la Santé, Université de Brest, Brest, France; LaTIM, Inserm, UMR 1101, CHU Brest, Brest, France
| |
Collapse
|
3
|
Marolleau J, Nguyen TA, Doucet L, Coste A, Schoentgen N, Rousseau B, Valeri A, Fournier G. [Morbidity of extended pelvic lymphadenectomy during robot-assisted laparoscopic prostatectomy for localized cancer prostate]. Prog Urol 2022; 32:1455-1461. [PMID: 36088200 DOI: 10.1016/j.purol.2022.07.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Revised: 07/02/2022] [Accepted: 07/18/2022] [Indexed: 11/30/2022]
Abstract
OBJECTIVES To assess the morbidity specific of extended pelvic lymphadenectomy during robot-assisted laparoscopic radical prostatectomy in a 8 year retrospective study. MATERIAL We carried out a single-center, single-surgeon retrospective study on 342 consecutive patients who underwent a robot-assisted laparoscopic radical prostatectomy and extended pelvic lymphadenectomy, from July 2010 to March 2018. Postoperative complications were recorded up to 3 months after the operation. RESULTS Thirty (8.8%) patients had at least one complication related to lymphadenectomy including 1 vascular injury (0.3%), 7 injuries of the obturator nerve (2%), 5 venous thromboembolic complications (1.5%) including 4 pulmonary embolisms, 10 symptomatic lymphoceles (2.9%) and 8 lymphoedemas (2.3%). Of these complications, 13 were classified Clavien 1 (43.3%), 8 Clavien 2 (26.7%), 7 Clavien 3a (23.3%) and 2 Clavien 3b (6.7%). In univariate analysis a high age (P=0.04), high BMI (P<0.01) and pT stage (P=0.02) were significantly associated with complication whereas in multivariate analysis, only age (P=0.02) and BMI (P<0.01) lived were. In univariate analysis high BMI (P=0.04) and lymph node involvement (P=0.04) were associated with lymphatic complication. We did not find any other specific risk factor for the other complications. CONCLUSION With 8.8% of overall complications related to lymphadenectomy and 5% of complication classified Clavien grade 2 or higher, extended pelvic lymphadenectomy was not very morbid. Age and BMI were risk factors for a overall complication. BMI and lymph node involvement were risk factors for lymphatic complications. LEVEL OF PROOF 4.
Collapse
Affiliation(s)
| | - T A Nguyen
- Service d'urologie, CHU, Brest, France; Faculté de Médecine et des Sciences de la Santé, Université de Bretagne Occidentale, Brest, France; LaTIM, Inserm, UMR 1101, Université de Bretagne Occidentale, Brest, France
| | - L Doucet
- Laboratoire d'anatomo-pathologie, CHU, Brest, France
| | - A Coste
- LaTIM, Inserm, UMR 1101, Université de Bretagne Occidentale, Brest, France; Service de médecine infectieuse et tropicale, CHU, Brest, France
| | | | | | - A Valeri
- Service d'urologie, CHU, Brest, France; Faculté de Médecine et des Sciences de la Santé, Université de Bretagne Occidentale, Brest, France; LaTIM, Inserm, UMR 1101, Université de Bretagne Occidentale, Brest, France; CeRePP, Paris, France
| | - G Fournier
- Service d'urologie, CHU, Brest, France; Faculté de Médecine et des Sciences de la Santé, Université de Bretagne Occidentale, Brest, France; LaTIM, Inserm, UMR 1101, Université de Bretagne Occidentale, Brest, France; CeRePP, Paris, France
| |
Collapse
|
4
|
Bendjelloul M, Usureau C, Etancelin P, Saidak Z, Lebon D, Garçon L, Marolleau J, Desoutter J, Guillaume N. Utility of assessing
CD3
+
cell chimerism within the first months after allogeneic hematopoietic stem‐cell transplantation for acute myeloid leukemia. HLA 2022; 100:18-23. [PMID: 35064642 PMCID: PMC9303291 DOI: 10.1111/tan.14557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Revised: 12/22/2021] [Accepted: 01/19/2022] [Indexed: 11/30/2022]
Affiliation(s)
- Mehdi Bendjelloul
- Department of Hematology and Histocompatibility Amiens University Medical Center Amiens France
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
| | - Cédric Usureau
- Department of Hematology and Histocompatibility Amiens University Medical Center Amiens France
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
| | | | - Zuzana Saidak
- Laboratory of Molecular Oncobiology, Center of Human Biology, Amiens‐Picardie University Medical Center Amiens France
| | - Delphine Lebon
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
- Department of Clinical Hematology and Cellular Therapy Amiens University Medical Center Amiens France
| | - Loïc Garçon
- Department of Hematology and Histocompatibility Amiens University Medical Center Amiens France
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
| | - Jean‐Pierre Marolleau
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
- Department of Clinical Hematology and Cellular Therapy Amiens University Medical Center Amiens France
| | - Judith Desoutter
- Department of Hematology and Histocompatibility Amiens University Medical Center Amiens France
| | - Nicolas Guillaume
- Department of Hematology and Histocompatibility Amiens University Medical Center Amiens France
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
| |
Collapse
|
5
|
Saout K, Zambon A, Nguyen T, Lucas C, Payrard-Starck C, Segalen T, Tissot V, Doucet L, Marolleau J, Deruelle C, Joulin V, Fourcade A, Fournier G, Valeri A. Impact of multiparametric MRI and PSA density on the initial indication or the maintaining in active surveillance during follow-up in low-risk prostate cancer. Clin Genitourin Cancer 2022; 20:e244-e252. [DOI: 10.1016/j.clgc.2022.01.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2021] [Revised: 01/12/2022] [Accepted: 01/17/2022] [Indexed: 11/25/2022]
|
6
|
Lam M, Touitou V, Choquet S, Cassoux N, Ghesquières H, Kodjikian L, Schmitt A, Gattoussi S, Tabouret É, Sampo M, Blonski M, Angioi‐Duprez K, Houot R, Mouriaux F, Gyan E, Le Lez M, Moles M, Croisé F, Chauchet A, Schwartz C, Ahle G, Meyer L, Gressin R, Chiquet C, Oberic L, Ollé P, Marolleau J, Jany B, Tempescul A, Cochener B, Damaj G, Quintyn J, Moluçon‐Chabrot C, Rousseau E, Franciane P, Schneider C, Massé H, Tamburini‐Bonnefoy J, Brézin A, Fornecker L, Ballonzoli L, Le Garff‐Tavernier M, Hoang‐Xuan K, Bodaghi B, Soussain C, Houillier C. Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study. Am J Hematol 2021; 96:823-833. [PMID: 33864703 DOI: 10.1002/ajh.26199] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2020] [Revised: 04/11/2021] [Accepted: 04/14/2021] [Indexed: 12/13/2022]
Abstract
The treatment of primary vitreoretinal lymphoma (PVRL) remains controversial regarding the use of local, systemic, or combined treatments. The aim of this study was to analyze the efficacy and toxicity of intravenous high-dose methotrexate (IV HD-MTX) based systemic therapy in a uniformly treated population of PVRL patients. From a nationwide French database, we retrospectively selected 59 patients (median age: 70 years, median Karnofsky Performance Status: 90%) with isolated PVRL at diagnosis who received first-line treatment with HD-MTX between 2011 and 2018. 8/59 patients also received a local treatment. No deaths or premature discontinuations of MTX due to toxicity were reported. A complete response was obtained in 40/57 patients after chemotherapy. Before treatment, IL-10 was elevated in the aqueous humor (AH) or in the vitreous in 89% of patients. After treatment, AH IL-10 was undetectable in 87% of patients with a CR/uCR/PR and detectable in 92% of patients with PD/SD. After a median follow-up of 61 months, 42/59 (71%) patients had relapsed, including 29 isolated ocular relapses as the first relapse and a total of 22 brain relapses. The median overall survival, progression-free survival, ocular-free survival and brain-free survival were 75, 18, 29 and 73 months, respectively. IV HD-MTX based systemic therapy as a first-line treatment for isolated PVRL is feasible, with acceptable toxicity, even in an elderly population. This strategy seems efficient to prevent brain relapse with prolonged overall survival. However, the ocular relapse rate remains high. New approaches are needed to improve local control of this disease, and ocular assessment could be completed by monitoring AH IL-10.
Collapse
Affiliation(s)
- Marion Lam
- Ophthalmology, Assistance Publique – Hôpitaux de Paris (APHP) Groupe Hospitalier Pitié‐Salpêtrière Paris France
- Sorbonne Université Paris France
| | - Valérie Touitou
- Ophthalmology, Assistance Publique – Hôpitaux de Paris (APHP) Groupe Hospitalier Pitié‐Salpêtrière Paris France
| | - Sylvain Choquet
- Hematology APHP, Groupe Hospitalier Pitié‐Salpêtrière, Sorbonne Université Paris France
| | - Nathalie Cassoux
- Ophthalmology, Institut Curie, Site Paris Université Paris V Descartes et PSL (Paris Science et Lettre) Paris France
| | - Hervé Ghesquières
- Hematology, Centre Hospitalier Lyon Sud Université Claude Bernard Lyon 1 Pierre‐Bénite France
| | - Laurent Kodjikian
- Ophthalmology, Croix‐Rousse University Hospital Université Claude Bernard Lyon 1 Lyon France
- Laboratoire UMR‐CNRS 5510 Matéis Université Lyon 1 Lyon France
| | | | - Sarra Gattoussi
- Ophthalmology Centre Hospitalier Universitaire de Bordeaux Bordeaux France
- University of Bordeaux, INSERM Bordeaux France
| | - Émeline Tabouret
- Neuro‐oncology, Assistance Publique – Hôpitaux de Marseille (AP‐HM), Timone Marseille France
- Aix‐Marseille Université, CRO2, UMR911 Marseille France
| | - Magali Sampo
- Ophthalmology Centre Hospitalier Intercommunal Toulon Toulon France
| | - Marie Blonski
- Neurology Centre Hospitalier Universitaire de Nancy Nancy France
| | - Karine Angioi‐Duprez
- Ophthalmology Centre Hospitalier Universitaire de Nancy, Université de Lorraine Nancy France
| | - Roch Houot
- Hematology Centre Hospitalier Universitaire de Rennes, Université de Rennes, INSERM U1236 Rennes France
| | - Frédéric Mouriaux
- Ophthalmology Centre Hospitalier Universitaire de Rennes Rennes France
| | - Emmanuel Gyan
- Hematology Centre Hospitalier Universitaire de Tours Tours France
| | | | | | - Fabien Croisé
- Ophthalmology Centre Hospitalier Universitaire de Angers Angers France
| | - Adrien Chauchet
- Hematology Centre Hospitalier Universitaire de Besançon, Hôpital Jean Minjoz Besançon France
| | - Claire Schwartz
- Ophthalmology Centre Hospitalier Universitaire de Besançon, Hôpital Jean Minjoz Besançon France
| | - Guido Ahle
- Neurology Hôpital Pasteur – Hôpitaux Civils de Colmar Colmar France
| | - Laurent Meyer
- Ophthalmology Hôpitaux civils de Colmar Colmar France
| | - Rémy Gressin
- Hematology Centre Hospitalier Universitaire de Grenoble Grenoble France
| | - Christophe Chiquet
- Grenoble Alpes University Grenoble France
- Ophthalmolgy Grenoble Alpes University Hospital Grenoble France
| | - Lucie Oberic
- Hematology Institut Universitaire du Cancer de Toulouse Oncopôle Toulouse France
| | | | | | - Benjamin Jany
- Ophthalmology Centre Hospitalier Universitaire de Amiens Amiens France
| | - Adrian Tempescul
- Hematology Centre Hospitalier Universitaire de Brest Brest France
| | - Béatrice Cochener
- Ophthalmology Centre Hospitalier Universitaire de Brest Brest France
| | - Gandhi Damaj
- Hematology Centre Hospitalier Universitaire de Caen, Université de Caen‐Normandie Caen France
| | | | | | - Eve Rousseau
- Ophthalmology Centre Hospitalier Universitaire de Gabriel Montpied Clermont‐Ferrand France
| | - Paul Franciane
- Hematology, Saint Eloi Hospital Montpellier University Hospital Montpellier France
| | - Christelle Schneider
- Ophthalmology Centre Hospitalier Universitaire Gui de Chauliac Montpellier France
| | - Hélène Massé
- Ophthalmology Centre Hospitalier Universitaire de Nantes Nantes France
| | | | | | | | - Laurent Ballonzoli
- Ophthalmology Centre Hospitalier Universitaire de Strasbourg Strasbourg France
| | | | - Khê Hoang‐Xuan
- Neurology APHP Sorbonne Université, IHU, ICM, Groupe Hospitalier Pitié‐Salpêtrière Paris France
| | - Bahram Bodaghi
- Ophthalmology, Assistance Publique – Hôpitaux de Paris (APHP) Groupe Hospitalier Pitié‐Salpêtrière Paris France
| | - Carole Soussain
- Hematology Institut Curie Site Saint‐Cloud Paris France
- INSERM U932, Institut Curie, PSL Research University Paris France
| | - Caroline Houillier
- Neurology APHP Sorbonne Université, IHU, ICM, Groupe Hospitalier Pitié‐Salpêtrière Paris France
| |
Collapse
|
7
|
Saout K, Zambon A, N’Guyen T, Lucas C, Payrard-Starck C, Marolleau J, Segalen T, Tissot V, Doucet L, Deruelle C, Joulin V, Fourcade A, Fournier G, Valeri A. Impact de la densité du PSA et de l’IRM multiparamétrique dans l’indication à une surveillance active d’un adénocarcinome prostatique à faible risque. Prog Urol 2020. [DOI: 10.1016/j.purol.2020.07.236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
Ollivier L, Lucia F, Lucas C, Bourbonne V, Marolleau J, Boussion N, Goasduff G, Fournier G, Dissaux G, Pradier O, Valeri A, Schick U. PO-1198: Comparison between built custom linked seeds and loose seeds in prostate brachytherapy. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01216-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Montes L, Tredez E, Yzet C, Delette C, Chatelain D, Lebon D, Fumery M, Marolleau J. Epstein-Barr Virus-related mucocutaneous ulcer lymphoma associated with Crohn's disease, treated with monoclonal antibody anti-CD30. Clin Case Rep 2020; 8:958-961. [PMID: 32577242 PMCID: PMC7303872 DOI: 10.1002/ccr3.2721] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2019] [Revised: 12/29/2019] [Accepted: 01/07/2020] [Indexed: 11/06/2022] Open
Abstract
Epstein-Barr virus-related mucocutaneous ulcer lymphoma is a rare entity promoted by immunosuppression. It is less described in inflammatory bowel diseases, and mostly these are refractory diseases. CD30 acts to Epstein-Barr virus (EBV) local proliferation and thus could be an interesting target. Brentuximab vedotin could become a new helpful tool.
Collapse
Affiliation(s)
- Lydia Montes
- Hematology and Cell Transplant DepartmentCHU AmiensAmiensFrance
| | | | - Clara Yzet
- Gastro‐enterology and Hepatology DepartmentCHU AmiensAmiensFrance
| | | | | | - Delphine Lebon
- Hematology and Cell Transplant DepartmentCHU AmiensAmiensFrance
| | - Mathurin Fumery
- Gastro‐enterology and Hepatology DepartmentCHU AmiensAmiensFrance
| | | |
Collapse
|
10
|
Dubert M, Le Toriellec E, Croisille L, Thomas L, Ducreux M, Froissart A, Herbrecht R, Lebrun‐Vignes B, Marolleau J, Méric J, Mahevas M, Michel M, Bierling P. Methylprednisolone-induced immune thrombocytopenia. Am J Hematol 2020; 95:E13-E16. [PMID: 31598982 DOI: 10.1002/ajh.25645] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2019] [Accepted: 09/30/2019] [Indexed: 02/03/2023]
Affiliation(s)
- Marie Dubert
- Service de Médecine InterneHôpital Henri Mondor Créteil France
| | - Emilie Le Toriellec
- Etablissement Français du Sang, Service d'Immunologie plaquettaire, Hôpital Henri Mondor Créteil France
| | - Laure Croisille
- Etablissement Français du Sang, Service d'Immunologie plaquettaire, Hôpital Henri Mondor Créteil France
| | - Laure Thomas
- Centre Régional de PharmacovigilanceHôpital Henri Mondor Créteil France
| | - Michel Ducreux
- Service d'Oncologie DigestiveInstitut Gustave Roussy Villejuif France
| | - Antoine Froissart
- Service de Médecine Interne, Centre hospitalier intercommunal de Créteil, Créteil France
| | - Raoul Herbrecht
- Université de Strasbourg, Inserm, UMR‐S1113 / IRFAC Strasbourg France
| | | | | | | | | | - Marc Michel
- Service de Médecine InterneHôpital Henri Mondor Créteil France
| | - Philippe Bierling
- Etablissement Français du Sang, Service d'Immunologie plaquettaire, Hôpital Henri Mondor Créteil France
- Université Paris Est Créteil (UPEC), INSERM U 955 Equipe 2 Créteil France
| |
Collapse
|
11
|
Nguyen T, Fourcade A, Payrard-Starck C, Tissot V, Marolleau J, Doucet L, Lucas C, Deruelle C, Joulin V, Fournier G, Valeri A. Faut-il encore biopsier les patients avec IRM prostatique normale ? Sur la piste de facteurs prédictifs de cancer prostatique. Prog Urol 2019. [DOI: 10.1016/j.purol.2019.08.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
12
|
Marmouset V, Joris M, Merlusca L, Beaumont M, Charbonnier A, Marolleau J, Gruson B. The lenalidomide/bortezomib/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm. Hematol Oncol 2019; 37:487-489. [DOI: 10.1002/hon.2671] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2019] [Revised: 08/22/2019] [Accepted: 08/24/2019] [Indexed: 01/01/2023]
Affiliation(s)
- Vincent Marmouset
- Department of Haematology Amiens University Medical Center Amiens France
| | - Magalie Joris
- Department of Haematology Amiens University Medical Center Amiens France
| | - Lavinia Merlusca
- Department of Haematology Amiens University Medical Center Amiens France
| | - Marie Beaumont
- Department of Haematology Amiens University Medical Center Amiens France
| | | | | | - Bérengère Gruson
- Department of Haematology Amiens University Medical Center Amiens France
| |
Collapse
|
13
|
Schoentgen N, Marolleau J, Valeri A, Rousseau B, Fournier G. Suivi à long terme après prostatectomie et curage ganglionnaire étendu d’une cohorte de patient atteint d’un cancer de prostate localisé avec envahissement ganglionnaire : intérêt du curage ? Prog Urol 2018. [DOI: 10.1016/j.purol.2018.07.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
Lamy T, Damaj G, Soubeyran P, Gyan E, Legouill S, Cartron G, Boubdallah K, Gressin R, Cornillon J, Banos A, Ledu K, Benchalal M, Moles M, Fleury J, Godmer P, Maisonneuve H, Deconninck E, Laribi K, Marolleau J, Tournilhac O, Deviller A, Fest T, Colombat P, Costes V, Bene M, Delwail V. R-CHOP +/-RADIOTHERAPY IN NON-BULKY LIMITED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): FINAL RESULTS OF THE PROSPECTIVE RANDOMIZED PHASE III 02-03 TRIAL FROM THE LYSA/GOELAMS. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- T. Lamy
- Hematology; CHU de Rennes; Rennes France
| | - G. Damaj
- Hematology; CHU de Caen; Caen France
| | | | - E. Gyan
- Hematology; CHU de Tours; Tours France
| | | | - G. Cartron
- Hematology; CHU Montpellier; Montpellier France
| | | | - R. Gressin
- Hematology; CHU de Grenoble; Grenoble France
| | - J. Cornillon
- Hematology; Insitut de Cancerologie; Saint Etienne France
| | - A. Banos
- Hematology; CH BAyonne; Bayonne France
| | - K. Ledu
- Hematology; Clinique du Mans; Le Mans France
| | - M. Benchalal
- Radiotherapy; Centre Eugene Marquis; Rennes France
| | - M. Moles
- Hematology; CHU d'Angers; Angers France
| | - J. Fleury
- Hematology; Pole Sante Republique; Clermont Ferrand France
| | - P. Godmer
- Hematology; CH Vannes; Vannes France
| | - H. Maisonneuve
- Hematology; Centre Hospitalier de Vendee; La Roche sur Yon France
| | | | - K. Laribi
- Hematology; Le Mans Hospital; France
| | | | - O. Tournilhac
- Hematology; Clermont Hospital; Clermont Ferrand France
| | - A. Deviller
- Nuclear Medicine; Centre Eugene Marquis; France
| | - T. Fest
- Hematology Biology; CHU de Rennes; Rennes France
| | | | - V. Costes
- Pathology; CHU Montpellier; Montpellier France
| | - M. Bene
- Hematology Biology; CHU de Nantes; Nantes France
| | - V. Delwail
- Hematology; Poitiers Hospital; Poitiers France
| |
Collapse
|
15
|
Salomon S, Guignant C, Brault C, Flahaut G, Gubler B, Fardellone P, Marolleau J, Goeb V. AB0025 Evolution of Regulatory B Cells under Treatment by Biologics in Rheumatoid Arthritis. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
16
|
Butler-Browne G, Périé S, Bouazza B, Svinartchouk F, Mamchaoui K, Marolleau J, Eymard B, Mouly V, Lacau St. Guily J. G.P.7.14 Protocol of autologous myoblast transplantation in the pharyngeal muscles to correct dysphagia in patients with oculopharyngeal muscular dystrophy. Neuromuscul Disord 2007. [DOI: 10.1016/j.nmd.2007.06.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Lefrere F, Makke J, Fermand J, Marolleau J, Dal Cortivo L, Alberti C, Mouton V, Benbunan M, Miclea J. Blood stem cell collection using chemotherapy with or without systematic G-CSF: experience in 52 patients with multiple myeloma. Bone Marrow Transplant 1999; 24:463-6. [PMID: 10482928 DOI: 10.1038/sj.bmt.1701910] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Harvesting of peripheral blood stem cells (PBSCs) following chemotherapy and G-CSF administration is currently performed for hematological therapies. However, a procedure based on the use of a large quantity of G-CSF is relatively costly. Therefore, we retrospectively compared the effects of two PBSC mobilization procedures in a population with recently diagnosed multiple myeloma. The first procedure consisted of chemotherapy and systematic G-CSF administration (group 1: 24 patients). The second consisted of chemotherapy alone, G-CSF having been administered only in the case of failure of PBSC mobilization or delayed white blood cell (WBC) recovery (group 2: 28 patients). Leukapheresis was performed when WBC recovery reached 1 x 10(9)/l if the peripheral blood CD34+ cell count was over 10/microl. Leukapheresis was maintained until a total of 2.5 x 10(6) CD34+ cells/kg was harvested. A significant difference was observed between the two groups only in regard to the median period of WBC recovery (delayed for group 2) and the number of CD34+ cells/kg collected on the first leukapheresis (higher for group 1) but not to the proportion of patients with failure of PBSC collection. Ten group 2 patients, who had insufficient CD34+ cells after WBC recovery or delayed WBC recovery, received G-CSF which resulted in sufficient PBSC harvesting in nine. To obtain a sufficient CD34+ cell level, the patients without systematic G-CSF administration had more leukaphereses (2.1 vs 1.5) but the mean consumption of G-CSF per patient was eight times less than in the other group. Nonsystematic use of G-CSF before WBC recovery or preferentially its introduction just after, could be an interesting economical alternative in PBSC mobilization but should be assessed by a prospective controlled study of cost/efficacy.
Collapse
Affiliation(s)
- F Lefrere
- Blood Bank Center, Etablissement APHP, Saint-Louis Hospital, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|